{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:20:36Z","timestamp":1761488436173,"version":"3.37.3"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/ftd.0b013e3181dca14b","type":"journal-article","created":{"date-parts":[[2010,5,5]],"date-time":"2010-05-05T06:40:20Z","timestamp":1273041620000},"page":"273-281","source":"Crossref","is-referenced-by-count":21,"title":["Can Therapeutic Drug Monitoring Improve Pharmacotherapy of HIV Infection in Adolescents?"],"prefix":"10.1097","volume":"32","author":[{"given":"Natella Y","family":"Rakhmanina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John N","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J","family":"Soldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Mordwinkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N","family":"Neely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/08892220260190290","article-title":"Position paper on therapeutic drug monitoring of antiretroviral agents.","volume":"18","author":"Acosta","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"Suppl 1","key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00002030-200203001-00002","article-title":"Therapeutic drug monitoring in HIV infection: current status and future directions.","volume":"16","author":"Back","year":"2002","journal-title":"AIDS"},{"key":"R4-9-20210129","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/clpt.2008.187","article-title":"Personalized therapeutics: HIV treatment in adolescents.","volume":"84","author":"Rakhmanina","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/0091270008321789","article-title":"Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.","volume":"48","author":"Neely","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00007691-200404000-00006","article-title":"Therapeutic drug monitoring in children with HIV\/AIDS.","volume":"26","author":"Fraaij","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1128\/AAC.01374-08","article-title":"Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children.","volume":"53","author":"Rakhmanina","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1128\/AAC.01594-08","article-title":"Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?","volume":"53","author":"Hirt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1542\/peds.109.4.e61","article-title":"Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.","volume":"109","author":"Van Dyke","year":"2002","journal-title":"Pediatrics"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/apc.2008.0162","article-title":"Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions.","volume":"23","author":"Rudy","year":"2009","journal-title":"AIDS Patient Care STDs"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1128\/AAC.46.3.884-886.2002","article-title":"International interlaboratory quality control program for measurement of antiretroviral drugs in plasma.","volume":"46","author":"Aarnoutse","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.ftd.0000162521.16060.13","article-title":"TDM: therapeutic drug measuring or therapeutic drug monitoring?","volume":"27","author":"Droste","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00007691-200310000-00001","article-title":"Improved method for concurrent quantification of antiretrovirals by liquid chromatography-tandem mass spectrometry.","volume":"25","author":"Ghoshal","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0009-9120(02)00286-2","article-title":"Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry.","volume":"35","author":"Volosov","year":"2002","journal-title":"Clin Biochem"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/FTD.0b013e31803258ed","article-title":"Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection.","volume":"29","author":"Rakhmanina","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00006454-200208000-00009","article-title":"Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.","volume":"21","author":"van Rossum","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/09540120410001665330","article-title":"Clinical assessment of medication adherence among HIV-infected children: examination of the Treatment Interview Protocol (TIP).","volume":"16","author":"Marhefka","year":"2004","journal-title":"AIDS Care"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/09540120020018161","article-title":"Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA.","volume":"13","author":"Murphy","year":"2001","journal-title":"AIDS Care"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.1542\/peds.2006-1232","article-title":"Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management.","volume":"119","author":"Simoni","year":"2007","journal-title":"Pediatrics"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1517\/14656560903376178","article-title":"The changing pattern of adherence to antiretroviral therapy assessed at two time points, 12 months apart, in a cohort of HIV-infected children.","volume":"10","author":"Giannattasio","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/adc.2008.156232","article-title":"Evaluating adherence to medication in children and adolescents with HIV.","volume":"94","author":"Khan","year":"2009","journal-title":"Arch Dis Child"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1054-139X(01)00341-X","article-title":"From adolescence through young adulthood: psychosocial adjustment associated with long-term survival of HIV.","volume":"30","author":"Battles","year":"2002","journal-title":"J Adolesc Health"},{"key":"R24-9-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10461-006-9133-3","article-title":"Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues.","volume":"11","author":"Pearson","year":"2007","journal-title":"AIDS Behav"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1542\/peds.2004-0085","article-title":"Integrating adherence to highly active antiretroviral therapy into childrens daily lives: a qualitative study.","volume":"114","author":"Hammami","year":"2004","journal-title":"Pediatrics"},{"key":"R26-9-20210129","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0090-9556(24)14935-5","article-title":"Identification and characterization of efavirenz metabolites by liquid chromatography\/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz.","volume":"27","author":"Mutlib","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R27-9-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R28-9-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/jpet.106.102525","article-title":"Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms.","volume":"318","author":"Bumpus","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R30-9-20210129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0b013e318040b29e","article-title":"Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.","volume":"45","author":"Saitoh","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R31-9-20210129","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/135965350901400316","article-title":"Plasma efavirenz concentrations and the association with CYP2B6-516G T polymorphism in HIV-infected Thai children.","volume":"14","author":"Puthanakit","year":"2009","journal-title":"Antivir Ther"},{"key":"R32-9-20210129","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"R33-9-20210129","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1086\/522764","article-title":"Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz.","volume":"45","author":"Lowenhaupt","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R34-9-20210129","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":"Impact of CYP2B6 983TC polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.","volume":"61","author":"Wyen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R35-9-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R38-9-20210129","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1128\/AAC.01537-08","article-title":"Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.","volume":"53","author":"Cabrera","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-9-20210129","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/clpt.2008.271","article-title":"Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.","volume":"85","author":"Arab-Alameddine","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R41-9-20210129","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1592\/phco.28.6.782","article-title":"Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature.","volume":"28","author":"Torno","year":"2008","journal-title":"Pharmacotherapy"},{"key":"R42-9-20210129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/jpet.104.068973","article-title":"Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles.","volume":"311","author":"Lang","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R43-9-20210129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","article-title":"High prevalence of the CYP2B6 516G-T(*6)6) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe.","volume":"64","author":"Nyakutira","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"R44-9-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-005-0092-9","article-title":"Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea.","volume":"62","author":"Mehlotra","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"R45-9-20210129","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/QAD.0b013e3282ef9695","article-title":"CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.","volume":"21","author":"Saitoh","year":"2007","journal-title":"AIDS"},{"key":"R46-9-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/135965350901400116","article-title":"Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.","volume":"14","author":"van Luin","year":"2009","journal-title":"Antivir Ther"},{"key":"R47-9-20210129","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1468-1293.2009.00718.x","article-title":"CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.","volume":"10","author":"Powers","year":"2009","journal-title":"HIV Med"},{"key":"R49-9-20210129","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1086\/501458","article-title":"Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.","volume":"42","author":"Nettles","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R50-9-20210129","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1592\/phco.21.5.424.34497","article-title":"A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.","volume":"21","author":"Cremieux","year":"2001","journal-title":"Pharmacotherapy"},{"key":"R51-9-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200847060-00001","article-title":"A review of the pharmacokinetics of abacavir.","volume":"47","author":"Yuen","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R52-9-20210129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00003495-200565030-00006","article-title":"Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.","volume":"65","author":"Lyseng-Williamson","year":"2005","journal-title":"Drugs"},{"key":"R53-9-20210129","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1177\/0091270008322908","article-title":"Population pharmacokinetics of tenofovir in AIDS patients.","volume":"48","author":"Gagnieu","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R54-9-20210129","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1365-2125.1999.00071.x","article-title":"Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients.","volume":"48","author":"Villani","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R55-9-20210129","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.2165\/00003495-200565160-00010","article-title":"Atazanavir: a review of its use in the management of HIV infection.","volume":"65","author":"Swainston Harrison","year":"2005","journal-title":"Drugs"},{"key":"R56-9-20210129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200847100-00005","article-title":"Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.","volume":"47","author":"Molto","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R57-9-20210129","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2125.2005.02455.x","article-title":"Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.","volume":"60","author":"Crommentuyn","year":"2005","journal-title":"Br J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181dca14b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T15:04:28Z","timestamp":1740063868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201006000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181dca14b","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}